CSPG4-targeting CAR-macrophages inhibit melanoma growth
Preprint
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies but has been clinically less effective in solid tumors. Engineering macrophages with CARs has emerged as a promising approach to overcome some of the challenges faced by CAR-T cells due to the macrophage’s ability to easily infiltrate tumors, phagocytose their targets, and reprogram the immune response. We engineered CAR-macrophages (CAR-Ms) to target chondroitin sulfate proteoglycan 4 (CSPG4), an antigen expressed in melanoma, and several other solid tumors. CSPG4-targeting CAR-Ms exhibited specific phagocytosis of CSPG4-expressing melanoma cells. Combining CSPG4-targeting CAR-Ms with CD47 blocking antibodies synergistically enhanced CAR-M-mediated phagocytosis and effectively inhibited melanoma spheroid growth in 3D. Furthermore, CSPG4-targeting CAR-Ms inhibited melanoma tumor growth in mouse models. These results suggest that CSPG4-targeting CAR-M immunotherapy is a promising solid tumor immunotherapy approach for treating melanoma. STATEMENT OF SIGNIFICANCE: We engineered macrophages with CARs as an alternative approach for solid tumor treatment. CAR-macrophages (CAR-Ms) targeting CSPG4, an antigen expressed in melanoma and other solid tumors, phagocytosed melanoma cells and inhibited melanoma growth in vivo . Thus, CSPG4-targeting CAR-Ms may be a promising strategy to treat patients with CSPG4-expressing tumors.Keywords
This publication has 60 references indexed in Scilit:
- Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR SignalingAdvanced Materials, 2024
- Don't eat me/eat me signals as a novel strategy in cancer immunotherapyHeliyon, 2023
- Genetic Modification of Primary Human Myeloid Cells to Study Cell Migration, Activation, and Organelle DynamicsCurrent Protocols, 2022
- Nanocomplex‐Mediated In Vivo Programming to Chimeric Antigen Receptor‐M1 Macrophages for Cancer TherapyAdvanced Materials, 2021
- Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunityThe Journal of Pathology, 2020
- Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicityCancer Immunology, Immunotherapy, 2020
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell, 2018
- Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017
- Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived XenograftsCell Reports, 2016
- Distribution and molecular characterization of a cell‐surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodiesInternational Journal of Cancer, 1981